Introduction
Sel f-monitoring of blood glucose (SMBG) is a key technology enabling people with diabetes to achieve nearnormoglycemia. Thus, it is important for SMBG devices to deliver reliable results. 1 Glucose readings that are higher than the actual blood glucose value can conceal hypoglycemia and/or result in incorrect treatment decisions such as an insulin overdose; conversely, falsely low results can mask hyperglycemia. 2 Delayed or incorrect treatment can exacerbate glycemic excursions, leading to worsening hyperglycemia and hypoglycemia. 3, 4 A number of studies have demonstrated a relationship between the use of SMBG and improved outcomes among people with diabetes, including decreased glycated hemoglobin levels and fewer disease-related complications. [5] [6] [7] However, in order to fully realize the benefits of SMBG, the values must be accurate and patients (people with diabetes) and health care professionals (HCPs) need to act on the SMBG information and incorporate it into therapy and self-care plans. 3, 8, 9 Therefore, it is imperative that SMBG results are accurate and precise.
The importance of accuracy in in vitro diagnostic medical devices has been recognized by several regulatory agencies and organizations, including the International Organization for Standardization (ISO), as evidenced by the call for more stringent standards and guidelines for the assessment of SMBG devices. [10] [11] [12] While blood glucose monitoring systems (BGMSs) demonstrate a high level of accuracy in the laboratory setting, it is critically important that people with diabetes and HCPs are able to achieve a similar high level of accuracy with BGMSs where they are most commonly used, in the home as well as in the HCP office. Ease of use is also an important consideration for patient adherence. A system that is easy to use will assist both trained medical professionals and people with diabetes who are naive to the system in obtaining accurate results using the BGMS.
The CONTOUR ® NEXT (CN) test strip (Bayer HealthCare LLC, Diabetes Care, Tarrytown, NY; hereinafter referred to as new test strip) in conjunction with a new portfolio of Bayer meters [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] achieves advanced performance in blood glucose monitoring both when used by trained laboratory personnel or during routine use by medical professionals or people with diabetes. The new test strip uses a flavin adenine dinucleotide-glucose dehydrogenase (FAD-GDH) enzyme and a proprietary phenothiazine electron mediator and algorithm to minimize errors during the testing process. This article will provide an overview of research studies involving the performance of the new test strip and the portfolio of blood glucose meters with which it is compatible.
The studies included in this article evaluated several BGMSs, each consisting of a blood glucose meter designed for use with the new test strip. The new platform includes the CONTOUR XT (CXT) BGMS [CONTOUR NEXT EZ (CNEZ) in the United States and Canada], the CONTOUR NEXT LINK (CNL) BGMS, the CONTOUR NEXT USB (CNUSB) BGMS, and the CN BGMS (Bayer HealthCare LLC, Diabetes Care, Tarrytown, NY; Table 1 ). Each meter has customizable "HI/LO" settings, premeal and postmeal markers, and the ability to track blood glucose patterns over time. In addition, each meter has a different set of features so that HCPs and their patients can select a system that can provide benefit 
Assessment Across the Test Strip Platform
The new platform of BGMSs that use the new test strip includes features such as underfill detection and provides the user with the ability to reapply blood when the test strip is underfilled ("second chance" sampling). Studies were conducted to evaluate the accuracy of blood glucose results obtained with the new test strip after a second application of blood was added to the test strip. 24 The new test strip results were accurate under conditions of blood sample reapplication, with 99.1% of results meeting the then-proposed ISO 15197:2013 accuracy criteria (discussed later). 24 Results obtained with the new test strip are unaffected by physiological/therapeutic concentrations of many common interfering substances as shown by test strip results demonstrating ≤1% bias (relative to a sample with no interferent present) in the presence of the maximum therapeutic concentration or upper reference value of the six most common endogenous and exogenous interfering substances (acetaminophen, uric acid, bilirubin, galactose, maltose, and ascorbic acid; Table 2 ). 25 However, the new test strips should not be used during or soon after xylose absorption testing, as xylose in the blood will interfere with the testing process (i.e., accuracy of the result). 26 The new test strip includes a special correction electrode that, in conjunction with an algorithm, allows the meter to compensate for a wide range (0-70%) of hematocrit levels. The results of laboratory tests conducted to demonstrate the accuracy of the new test strip over a wide range of hematocrit levels are shown in Figure 1 as the bias of test results at different levels of hematocrit relative to Yellow Springs Instruments (YSI) reference results (data on file). Fresh venous blood samples were adjusted to hematocrit levels of 0%, 40%, and 70% and tested using three lots (n = 24 per lot per glucose level) of test strips. The results showed <10 mg/dl bias at plasma glucose levels of 50 mg/dl and <10% bias at plasma glucose levels of 120 and 450 mg/dl over the hematocrit range of 0% to 70% (Figure 1) . The BGMSs using the new test strip are also functional over a wide range of humidity (10-93% relative humidity) and temperature [41-113 °F (5-45 °C)], as specified in their respective labeling. [27] [28] [29] [30] Analytical Performance (ISO 15197:2003 Section 7 and ISO 15197:2013 Section 6.3)
Laboratory studies were conducted to assess the analytical accuracy of each meter system that includes the new test strip based on the ISO 15197:2003 section 7 protocol and the ISO 15197:2013 section 6.3 protocol. 31, 32 In each study, capillary finger stick blood samples from 100 subjects were tested by laboratory professionals in duplicate using each of three lots of test strips to obtain a total of 600 blood glucose test results. [13] [14] [15] [16] a The concentration of the interfering substance resulting in a ±10% bias of test results as determined by interpolation using linear regression analysis. If a substance did not have a concentration that created a ±10% bias, then the limiting concentration is listed as the highest level tested. b Ascorbic acid, bilirubin, cholesterol, triglycerides, and uric acid occur naturally in the body, so the effect at the limiting concentration was calculated with respect to the normal concentration rather than 0 mg/dl. c At five times the maximum therapeutic concentration, results showed a 10% assay bias at 80 mg/dl plasma glucose.
Accuracy was assessed according to ISO 15197:2003 performance criteria (i.e., ≥95% of results shall fall within ±15 mg/dl or ±20% of the reference result for samples with glucose concentrations <75 and ≥75 mg/dl, respectively). 31 Accuracy was also assessed based on the then-proposed ISO 15197:2013 accuracy criteria (i.e., ≥95% of results shall fall within ±15 mg/dl or ±15% of the reference result for samples with glucose concentrations <100 and ≥100 mg/dl, respectively) 32 as well as the percentage of BGMS results that fell within tighter specific error limits of the YSI reference results (e.g., ≥95% of results shall fall within ±10 mg/dl or ±10% of the reference result for samples with glucose concentrations <100 and ≥100 mg/dl, respectively).
The results of the analytical performance evaluations are summarized in Table 3 . When compared with YSI reference results, 100% of results obtained using the new test strip platform with various types of meters met the ISO 15197:2003 section 7 accuracy criteria across all four studies ( Table 3) . [13] [14] [15] [16] 33 Similarly, 100% of results obtained using the CXT/CNEZ BGMS, the CNL BGMS, or the CNUSB BGMS and 99.8% of results obtained using the CN BGMS met the then-proposed ISO 15197:2013 accuracy criteria ( Table 3) . 13 Table 3 and Figure 2 ). [14] [15] [16] 33 Evaluation of clinical accuracy using Parkes consensus error grid analysis 34 showed that 100% of results were within zone A with all meter types used in the study ( Table 3 ). [14] [15] [16] The percentage of BGMS results that fell within specific error limits of the YSI reference result for each study is shown in Table 4 . For samples with glucose concentrations <75 mg/dl, ≥98.7% of results were within ±10 mg/dl of reference results across all four studies ( Table 4 ). 33 For samples with glucose concentrations ≥75 mg/dl, ≥98.1% of results were within ±10% of reference results for all systems ( Table 4 ). 33 Using combined glucose concentration thresholds of <75 and ≥75 mg/dl, ≥98.3% of results were within ±10 mg/dl or ±10%, respectively, of the reference result ( Table 4 ). 33 Similar results were observed using combined glucose concentration thresholds of <100 and ≥100 mg/dl; ≥98.5% of results were within ±10 mg/dl or ±10%, respectively, of the reference result ( Table 4) . 33 The new test strip was also evaluated against laboratory instruments more commonly used outside the United States. The test strip also demonstrated advanced accuracy when comparing the CXT/CNEZ BGMS with a Dimension EXL chemistry analyzer (Siemens Healthcare Diagnostics, Deerfield, IL) that uses the hexokinase reference method for glucose measurement. 35 One hundred samples were analyzed by both meters, and evaluation of accuracy showed that 100% of results obtained with the CXT/CNEZ BGMS met ISO 15197:2003 accuracy criteria and ≥99% of results met the then-proposed ISO 15197:2013 accuracy criteria. Similar to results obtained using the YSI reference method, the regression analysis R 2 for the comparison with the hexokinase method was >0.99. 35
User Performance Evaluation (ISO 15197 Section 8)
It is critical that BGMSs perform well in the hands of the intended user population, people with diabetes and their HCPs, as well as under controlled laboratory conditions. Lay user performance evaluations of the new test strip were conducted in several clinical trials, which assessed the accuracy of the system when used by untrained lay people with diabetes and HCPs. [17] [18] [19] [20] [21] [22] [23] In each study, subjects who were naive to the system learned how to use the BGMS by reading the user and quick reference guides provided with the device and tested their own blood. Health care professionals also tested blood samples from subjects on the BGMS following the subject-performed testing. All BGMS results were compared with YSI reference results. Accuracy was assessed based on ISO 15197:2003 accuracy criteria and the then-proposed ISO 15197:2013 accuracy criteria.
Results of the clinical trials evaluating user performance are summarized in Table 5 . The CXT/CNEZ BGMS and the CNL BGMS were each evaluated in two clinical studies, while the CNUSB BGMS and the CN BGMS were each evaluated in a single clinical study. [17] [18] [19] [20] [21] [22] [23] In all six studies, subjects tested their own capillary finger stick blood samples; ≥98.9% and ≥97.2% of results met ISO 15197:2003 and ISO 15197:2013 accuracy criteria, respectively ( Table 5) . 17, [19] [20] [21] [22] [23] 36 Three studies evaluated the accuracy of palm alternate site testing (AST) with the CNL BGMS, the CNUSB BGMS, or the CN BGMS. 19, 21, 22 In all three studies, ≥97.3% and ≥96.3% of palm AST results met ISO 15197:2003 and ISO 15197:2013 accuracy criteria, respectively ( Table 5) . 19, [21] [22] [23] The new BGMS platform also demonstrated enhanced accuracy when used by HCPs to test capillary blood samples from subjects. In studies that evaluated the CXT/CNEZ BGMS or the CNL BGMS, ≥99.5% of results from HCP testing of subject finger stick blood met both ISO 15197:2003 and ISO 15197:2013 accuracy criteria ( Table 5) . 17, 20, 22, 23 In studies that evaluated the CXT/CNEZ BGMS, the CNUSB BGMS, or the CN BGMS, HCPs also tested venous samples from subjects and compared the results with venous blood measured on the YSI. [19] [20] [21] In all three studies, 100% of venous results met both ISO 15197:2003 and ISO 15197:2013 accuracy criteria ( Table 5 ). [19] [20] [21] Regression analyses of BGMS results demonstrated strong correlation with reference results for the five studies for which regression analysis results were reported (R 2 >98% for finger stick and venous blood samples and >96% for AST samples; Table 5 ). 17, [19] [20] [21] [22] [23] Evaluation of clinical accuracy using Parkes consensus error grid analysis 34 showed that the majority of BGMS results (≥98.9% of finger stick results, ≥97.2% of AST results, and 100% of venous results) were in zone A (i.e., no effect on clinical action) for all six studies ( Table 5) . 17, [19] [20] [21] [22] 36 All remaining BGMS results (≤1.1% of finger stick results and ≤2.8% of AST results) were within zone B (i.e., altered clinical action with little or no effect on clinical outcome); there were no results in zones C, D, or E (i.e., altered clinical action with increasingly severe effect on clinical outcome) for any of the systems. 17, [19] [20] [21] [22] 36 Subjects in the six clinical studies reported that the new BGMS platform was easy to use. Additionally, the six clinical studies assessed meter features. Also, four of the six studies evaluated subject opinions regarding BGMS accuracy and diabetes management in general via subject questionnaires. Subject ease of use ratings from the clinical studies of the new BGMS platform are summarized in Figure 3 . In all four studies, most subjects responded that they agreed or strongly agreed that the BGMS was easy to use (≥92%), the user guide instructions were easy to understand (≥86%), Bernstein www.jdst.org J Diabetes Sci Technol Vol 7, Issue 5, September 2013 the meter display was easy to read (≥96%), and it was easy to see and understand the test results (≥95%; Figure 3) . 17, 19, 21, 22 In the CN BGMS study, 93.8% of subjects agreed or strongly agreed that the meter summary screen could help them understand how they are doing with their diabetes. 21 The CXT/CNEZ BGMS and CNL BGMS studies also assessed overall satisfaction with the BGMS, and the majority of subjects (98.9% and 99%, respectively) rated their overall satisfaction with the BGMS as "good" to "excellent" on subject questionnaires. 18, 20 The majority of subjects rated specific features of the CNL BGMS as "good" to "excellent," including ease of using the autolog feature (100%), ability to adjust target ranges (96%), lighted test strip port (96%), and ease of accessing (100%) and usefulness (98%) of the TRENDS menu. 18 Figure 3 . Ease of use of the new BGMS platform as assessed by subject questionnaire. 17, 19, 21, 22 Subjects in four of the six clinical studies completed a second questionnaire that assessed general attitudes regarding BGMS accuracy. In each study, most subjects agreed or strongly agreed that accuracy is important to help with: their ability to manage their diabetes (≥94%); preventing low blood sugar (89%); and using their results to manage their diabetes (≥96%; Figure 4) . 19, 21, 37 Approximately half of subjects in each study indicated that they would continue to use the meters and test strips for which they are reimbursed by their insurance company even if a more accurate meter was available, thus implying that the other half of subjects consider accuracy a more important factor than cost when selecting a meter (Figure 4) . 19, 21, 23, 37 In addition, in studies that evaluated the CNL BGMS or the CNUSB BGMS, 70% and 79% of subject questionnaire respondents, respectively, agreed or strongly agreed that they would switch meters for a more accurate meter. 19, 23 
Comparative Accuracy
The accuracy of the CXT/CNEZ BGMS was evaluated in comparison with the hexokinase reference method in a study conducted at the Quakenbrück Hospital in Germany. 38 The secondary objective of the study was to compare the accuracy of the CXT/CNEZ BGMS with the ACCU-CHEK ® Aviva (ACA; Roche Diagnostics, Indianapolis, IN) and OneTouch ® Verio ® (OTV; LifeScan Inc., Milpitas, CA) systems. 38 In this study, a trained HCP tested capillary finger stick samples that were previously collected from 110 subjects using each of the meter systems. 38 Accuracy was assessed according to the then-proposed ISO 15197:2013 accuracy criteria. Results of the comparative accuracy evaluations are summarized in Table 6 . Overall, 100% of results obtained using the CXT/CNEZ BGMS met the ISO 15197:2013 accuracy guidelines, compared with 98.2% of ACA results and 96.4% of OTV results ( Table 6 ). 38 Analysis of variance results showed that the CXT/CNEZ BGMS had lower mean absolute relative differences (MARDs) versus reference results than the OTV system and the ACA system ( Table 6 ). 38 Lower MARD values indicate less variation from the reference value and thus greater comparative accuracy. These differences were statistically significant for two of the three test strip lots used versus the ACA system and for all three test strip lots used versus the OTV system. 38 Another study conducted using the YSI reference method evaluated the CXT/CNEZ BGMS in comparison with the TRUEtrack ® (TT; Nipro Diagnostics Inc., Fort Lauderdale, FL), FreeStyle Freedom Lite ® (FFL; Abbott Diabetes Care Inc., Alameda, CA), OneTouch Ultra ® 2 (OTU2; LifeScan Inc., Milpitas, CA), and ACA systems (data on file). In this sponsor-investigator study, a trained operator tested unmodified capillary blood samples from 146 subjects using each of the five systems. One sample per subject was tested without modification, and up to two additional blood samples were glycolyzed to safely lower blood glucose to <70 mg/dl; 242 glycolyzed samples were tested with each of the five BGMSs. The accuracy of the BGMSs was compared using MARD. The CXT/CNEZ BGMS had the lowest MARD versus reference results of 4.7%, while the TT, FFL, OTU2, and ACA systems had MARD estimates of 26.2%, 18.3%, 23.4%, and 6.3%, respectively, across the overall tested glucose range (24-386 mg/dl; Table 7 ). In addition, for samples with glucose concentrations <70 mg/dl, the CXT/CNEZ BGMS had the lowest MARD versus reference results of 0.7% compared with the TT (33.2%), FFL (18.3%), OTU2 (22.4%), and ACA (2.5%) systems ( glucose-oxidase-based BGMSs (TT and OTU2) may be affected by glycolysis-induced changes in oxygen concentration, and thus unmodified samples were also evaluated. The CXT also had the lowest MARD values in all glucose ranges in unmodified samples ( Table 7) .
Conclusions
In diabetes management, both patients and HCPs need to incorporate SMBG data into therapy and self-care plans in order to maximize the benefits of SMBG. One study, which assessed differences between self-reported estimates of blood glucose values and those measured on a blood glucose meter, reported that 58% of subjects estimated blood glucose values were more than ±15 mg/dl or ±15% of meter glucose values <100 and ≥100 mg/dl, respectively. 39 
